Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering

Impact · against what's priced in

Lycia Therapeutics has successfully entered the public market with an upsized IPO, securing $317.5 million in gross proceeds. This provides the company with significant capital to fund its clinical development of therapeutics for autoimmune and inflammatory diseases.

LYCA+0.60

No priced-in read yet

In context

The company priced an upsized IPO of 17,640,000 shares at $18.00 per share, raising approximately $317.5 million for clinical development.

Read from the article alone

• biotech▲7%
• ipo
• healthcare
• LYCA
• autoimmune
• clinical stage
• pricing

Top 1 mover · tap to explore